Fully human antibody targeting gprc5d and chimeric antigen receptor (car) and use thereof
OwnerTaochao TAN, Qian LUO +8inventors
InventorsTaochao TAN, Qian LUO, Zhenyu DAI, Qiaoe WEI, Ya ZHAO, Yanying ZHANG, Jianwei LIU, Xiangyin JIA, Qianqian ZHANG, Meng XIE
Life of this patent
Estimating the term…
Abstract
A fully human antibody targeting GPRC5D and a chimeric antigen receptor (CAR) comprising the fully human antibody. A host cell expressing the CAR, such as a CAR-T cell. A use of the fully human antibody, the CAR, and the CAR-T cell in treatment of tumors (such as multiple myeloma).
Claims38
A GPRC5D binding peptide, comprising a heavy chain variable region of an antibody molecule, wherein the heavy chain variable region comprises a heavy chain complementarity determining region 1 (HCDR1), a heavy chain complementarity determining region 2 (HCDR2), and a complementarity determining region 3 (HCDR3), and wherein the HCDR1, HCDR2 and HCDR3 in the heavy chain variable region are selected from one of the following combinations:
- 1) HCDR1 is
- (SEQ ID NO:
- 1)
- GGSFSGYY;
- HCDR2 is
- (SEQ ID NO:
- 2)
- INHSGST;
- HCDR3 is
- (SEQ ID NO:
- 3)
- ARARRYGGRTRFDP;
- 2) HCDR1 is
- (SEQ ID NO:
- 4)
- GFIFSSYG;
- HCDR2 is
- (SEQ ID NO:
- 5)
- ISSSGDYT;
- HCDR3 is
- (SEQ ID NO:
- 6)
- ARMSFRRYDH;
- and
- 3) HCDR1 is
- (SEQ ID NO:
- 7)
- GFSFSGYI;
- HCDR2 is
- (SEQ ID NO:
- 8)
- TSSSGTET;
- HCDR3 is
- (SEQ ID NO:
- 9)
- ARYYSKYGRSYHVDS.
(canceled)
-6. (canceled)
-17. (canceled)
(canceled)
-25. (canceled)
-29. (canceled)
-32. (canceled)
-38. (canceled)
(canceled)
-49. (canceled)
-53. (canceled)
(canceled)
-67. (canceled)
(canceled)
-72. (canceled)
-77. (canceled)
-80. (canceled)
Dependencies are inferred from the claim text.